01 Membrane Filtration Systems Improve Controlled Plasma Separation Plasmapheresis machines market analysis shows that the need for automated and controlled plasma collection is shifting equipment toward membrane-based separation systems that process whole blood while returning concentrated cellular components to the donor. In January 2025, the FDA cleared Fresenius Kabi's Aurora Xi software update for a system that uses membrane filtration and supports automated plasma collection volumes of up to 1,098 mL of plasma product per donation. This transition improves collection control while supporting higher-volume plasma processing in donor centers.
02 Single-Use Disposable Sets Strengthen Infection-Control Practices Infection-control requirements are shifting plasmapheresis equipment toward single-use processing sets that provide a sterile fluid path for each procedure. In March 2026, the FDA cleared the Plasmacell-C Disposable Set for plasma collection by membrane filtration, with the set consisting of a separation device, reservoir, tubing, and connectors and sterilized by radiation. This transition reduces the need for reusable blood-contact components while supporting standardized and controlled plasma collection workflows.
01 Autoimmune and Neurological Disorder Prevalence and Hospital Apheresis Expansion Drive Market A growing burden of autoimmune and neurological disorders increases the need for therapeutic plasma exchange in hospitals and specialized treatment centers. Conditions such as Guillain-Barré syndrome and myasthenia gravis commonly require plasma exchange to remove disease-causing antibodies from circulation. A 2025 study from a tertiary hospital in western India reported that neurological conditions accounted for 76.9% of patients receiving therapeutic plasma exchange, with Guillain-Barré syndrome as the leading indication. This expanding clinical application strengthens demand for plasmapheresis machines.Expansion of specialized apheresis services increases the installed base of equipment required for therapeutic plasma exchange and other blood-component procedures. Hospitals with dedicated transfusion medicine and apheresis units can provide treatment closer to patients while supporting repeated procedures for complex conditions. A 2025 clinical report from Jehangir Hospital in Pune documented 152 therapeutic plasma exchange procedures performed using an apheresis machine, illustrating the application within tertiary-care settings. This broader clinical infrastructure supports equipment procurement and strengthens the market for plasmapheresis machines.
01 High Plasmapheresis Costs and Apheresis Specialist Shortages Restrain Market Expansion High equipment, maintenance, and servicing costs can make plasmapheresis machines difficult to procure for smaller hospitals and healthcare facilities. Limited budgets can delay equipment purchases and restrict the development of new apheresis units. Higher ownership costs therefore slow adoption and limit market expansion across cost-sensitive healthcare systems.Limited availability of professionals trained in apheresis procedures can restrict hospitals from operating plasmapheresis services at full capacity. Specialized training requirements can increase staffing challenges and make new service units more difficult to establish. This workforce gap can reduce equipment utilization and slow the expansion of therapeutic plasma exchange services.
01 Plasmapheresis Expansion in Emerging Markets and Critical Care Applications Offer Growth Opportunities Medical-device manufacturers, private hospitals, and apheresis service providers can expand plasmapheresis capabilities in underserved healthcare markets where specialized treatment access remains limited. New hospital installations, equipment sales, service contracts, and operator-training programs can create recurring revenue opportunities. Terumo BCT received 2025 approvals for additional therapeutic apheresis indications in 14 Latin American countries, demonstrating an active pathway for geographic expansion, contributing to the plasmapheresis machines market growth.Apheresis technology providers and specialized hospitals can develop treatment solutions for critical-care conditions where therapeutic plasma exchange or related blood-purification approaches may support patient management. New clinical applications can generate revenue through machine procurement, procedure services, and specialized treatment protocols. Terumo BCT and Santersus began a 2025 collaboration to advance therapeutic apheresis technology for sepsis treatment, illustrating this emerging application avenue.
March 2026 Terumo Blood and Cell Technologies introduced the APAC Cell & Gene Therapy Ecosystem Blueprint, a collaborative framework designed to accelerate adoption of advanced apheresis and cell-processing technologies across Asia-Pacific, strengthening infrastructure for therapeutic plasma and cell collection workflows.
February 2026 Terumo Blood and Cell Technologies announced that SunCoast Blood Centers became the first blood center in Florida and the ninth in the U.S. to deploy the FDA-cleared Reveos™ Automated Blood Processing System, expanding automation in blood and plasma processing operations.
September 2025 CSL Plasma and Terumo Blood and Cell Technologies completed the nationwide rollout of the Rika™ Plasma Donation System across all CSL Plasma centers in the United States. The deployment expanded the use of next-generation automated plasma collection technology to improve donor experience and collection efficiency.